Mirum Pharmaceuticals Inc. - notizie pubblicate 214 - letture 2.266
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Foster city, calif.--(business wire)-- mirum pharmaceuticals, inc. (nasdaq: mirm) today announced that on august 9, 2024, the compensation committee of mirum's board of directors g ...
MIRUM PHARMACEUTICALS INC.
Quarterly Report for Quarter Ending June 30, 2024 (Form 10-Q)
Mirm-20240630 table of contents united states securities and exchange commission washington, d.c. 20549 ____________________________________________________________________________ ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update Form 8 K
Mirum pharmaceuticals reports second quarter 2024 financial results and provides business update •second quarter global net product sales of $77.8 million, on track to achieve fu ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Second quarter global net product sales of $77.8 million, on track to achieve full-year guidance of $310 to $320 million positive interim results for volixibat in vistas psc and va ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024
Foster city, calif.--(business wire)-- mirum pharmaceuticals, inc. (nasdaq: mirm) today announced that it will report second quarter 2024 financial results on august 7, 2024. mirum ...
MIRUM PHARMACEUTICALS INC.
Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older
Foster city, calif.--(business wire)-- mirum pharmaceuticals, inc. (nasdaq: mirm) today announced that the u.s. food and drug administration (fda) has approved a label expansion fo ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Foster city, calif.--(business wire)-- mirum pharmaceuticals, inc. (nasdaq: mirm) today announced that on july 10, 2024, the compensation committee of mirum's board of directors gr ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC
European commission grants livmarli marketing authorization for treatment of pfic in patients three months and older. approval follows positive opinion from chmp concluding livmarl ...
MIRUM PHARMACEUTICALS INC.
Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX
Submission based on the positive phase 3 restore study mirum holds orphan designation for chenodiol in ctx potential to have first and only therapy indicated for ctx in the us fost ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
- vantage pbc interim analysis shows 3.8 point reduction from baseline and 2.3 point placebo-adjusted (p=0.0026) reduction in primary endpoint of pruritus - vistas psc interim anal ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024
Foster city, calif.--(business wire)-- mirum pharmaceuticals, inc. (nasdaq: mirm) today announced that it will host an investor call on monday, june 17 at 8:30 a.m. et to share int ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Foster city, calif.--(business wire)-- mirum pharmaceuticals, inc. (nasdaq: mirm) today announced that on june 10, 2024, the compensation committee of mirum's board of directors gr ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti